Materials Today Advances, Volume 13, March 2022
In this review, the authors summarize the latest understanding on the detection, concentration, and evaluation of SARS-CoV-2 in wastewater.
Elsevier, The Lancet Public Health, Volume 7, February 2022
The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study
Background: A considerable proportion of people who inject drugs are unstably housed. Although unstable housing is associated with HIV and HCV infection among people who inject drugs, its contribution to transmission is unknown. We estimated the global and national proportions of incident HIV and HCV infections among people who inject drugs attributed to housing instability from 2020 to 2029.
Elsevier, The Lancet, Volume 398, 30 October 2021
Vaccine, Volume 39, 23 August 2021
Hepatitis B (HB) vaccination plays a significant role in controlling HBV infection. Different immune mechanisms govern anti-HBs acquisition, titer, and maintenance. Host pre-vaccination immunological status could be targeted for vaccine efficacy.
Elsevier, Antiviral Research, Volume 186, February 2021
HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals
Hepatitis B virus (HBV) poses a major global health burden with 260 million people being chronically infected and 890,000 dying annually from complications in the course of the infection. HBV is a small enveloped virus with a reverse-transcribed DNA genome that infects hepatocytes and can cause acute and chronic infections of the liver. HBV is endemic in humans and apes representing the prototype member of the viral family Hepadnaviridae and can be divided into 10 genotypes.
Elsevier, The Lancet Global Health, Volume 8, March 2020
Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis
Background: The WHO elimination strategy for hepatitis C virus advocates scaling up screening and treatment to reduce global hepatitis C incidence by 80% by 2030, but little is known about how this reduction could be achieved and the costs of doing so. We aimed to evaluate the effects and cost of different strategies to scale up screening and treatment of hepatitis C in Pakistan and determine what is required to meet WHO elimination targets for incidence.
Elsevier, The Lancet Gastroenterology and Hepatology, Volume 2, December 2017
Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030
In 2016, WHO adopted a strategy for the elimination of viral hepatitis by 2030. Africa, and more specifically, sub-Saharan Africa, carries a substantial portion of the global burden of viral hepatitis, especially chronic hepatitis B and hepatitis C virus infections. The task that lies ahead for sub-Saharan Africa to achieve elimination is substantial, but not insurmountable. Major developments in the management of hepatitis C have put elimination within reach, but several difficulties will need to be navigated on the path to elimination.
Elsevier, The Lancet HIV, Volume 4, November 2017
New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004–15: an analysis of surveillance data
Background The HIV burden is increasing in older adults in the European Union (EU) and European Economic Area (EEA). We investigated factors associated with HIV diagnosis in older adults in the 31 EU/EEA countries during a 12 year period. Methods In this analysis of surveillance data, we compared data from older people (aged ≥50 years) with those from younger people (aged 15–49 years). We extracted new HIV diagnoses reported to the European Surveillance System between Jan 1, 2004, and Dec 31, 2015, and stratified them by age, sex, migration status, transmission route, and CD4 cell count.
Elsevier, The Lancet Planetary Health, Volume 1, July 2017
Elsevier, The Lancet HIV, Volume 3, 1 August 2016
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015
Background Timely assessment of the burden of HIV/AIDS is essential for policy setting and programme evaluation. In this report from the Global Burden of Disease Study 2015 (GBD 2015), we provide national estimates of levels and trends of HIV/AIDS incidence, prevalence, coverage of antiretroviral therapy (ART), and mortality for 195 countries and territories from 1980 to 2015.